The U.S. Food and Drug Administration has initiated a pilot program aimed at expediting the regulatory review of generic drugs that are tested, manufactured, and sourced entirely within the United States. This initiative forms part of broader policy efforts to reshore pharmaceutical manufacturing and strengthen domestic supply chains, with implications for affordability and drug accessibility.